摘要：胃食管交界腺癌发生于食管、胃的交界处，发病率高，现有的多学科治疗方法预后不佳。近年来，研究发现胃食管交界腺癌免疫检查点CTLA-4和PD-1/PD-L1的抑制剂，能够减少肿瘤细胞免疫逃逸，提高抗肿瘤作用，为患者带来更多生存获益。围手术期胃食管交界腺癌新辅助/辅助联合免疫疗法，可提高病理完全缓解率和手术成功率，能更大程度地降低术后肿瘤复发转移率，延长患者生存周期。本文就免疫治疗在可切除胃食管交界腺癌中的研究现状作一综述，以期为可切除胃食管交界腺癌的治疗及研究提供新思路。

    关键词：可切除胃食管交界腺癌;免疫治疗;免疫检查点抑制剂

    中图分类号：R735 文献标识码：A DOI：10.3969/j.issn.1006-1959.2024.20.041

    文章编号：1006-1959(2024)20-0188-05

    Research Status of Immunotherapy for Resectable Gastroesophageal Junction Adenocarcinoma

    SUN Jiawen1，2，ZHAO Xiaoling2，ZHANG Xiaochong2，WANG Jitao2，LIU Dengxiang2

    (1.Graduate School of Chengde Medical University，Chengde 067000，Hebei，China;

    2.Cancer Laboratory of Xingtai People's Hospital，Xingtai 054000，Hebei，China)

    Abstract：Adenocarcinoma of the gastroesophageal junction occurs at the junction of the esophagus and the stomach， with a high incidence. The prognosis of the existing multidisciplinary treatment is poor. In recent years， studies have found that inhibitors of immune checkpoints CTLA-4 and PD-1/PD-L1 in gastroesophageal junction adenocarcinoma can reduce tumor cell immune escape ......